Referanslar

1. Stevens A, Johnson F. A new eruptive fever associated with stomatitis and ophtalmia; report on two cases in children. Am J Dis Child. 1922;24:526-33 [Crossref]
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling calding of the skin. Br J Dermatol. 1956;68(11):355-61. [Crossref]  [PubMed]
3. Pichler WJ. Delayed drug hypersensitivity reactions. AnnIntern Med 2003;139(8):683-93. [Crossref]  [PubMed]
4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, StevensJohnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6.. [Crossref]  [PubMed]
5. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43-7. [Crossref]  [PubMed]
6. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson Syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387-97. [Crossref]  [PubMed]
7. Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76 (5):811- 7.e814. [Crossref]  [PubMed]  [PMC]
8. Rzany B, Hering O, Mockenhaupt M, Schroder W, Goerttler E, Ring J, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135(1):6-11 [Crossref]  [PubMed]
9. Prieto-Barrios M, Velasco-Tamariz V, TousRomero F, Burillo-Martinez S, Zarco-Olivo C, Rodriguez-Peralto JL, et al. Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. Br J Dermatol. 2017. [Crossref]  [PubMed]
10. Adler NR, McLean CA, Aung AK, Goh MS. Piperacillintazobactam-induced linear IgAbullous dermatosis presenting clinically as Stevens-Johnson syndrome/toxic epidermal necrolysis overlap. Clin Exp Dermatol. 2017; 42(3):299-302. [Crossref]  [PubMed]
11. Yamada T, Nakamura S, Demitsu T, Nakamura T, Iida E, Yoneda K, et al. Paraneoplastic pemphigus mimicking toxic epidermal necrolysis associated with B-cell lymphoma.J Dermatol 2013;40(4):286-8. [Crossref]  [PubMed]
12. Naik H, Lockwood S, Saavedra A. A pilot study comparing histological and immunophenotypic patterns in stage 4 skin graft vs host disease from toxic epidermal necrolysis. J Cutan Pathol. 2017. [Crossref]  [PubMed]
13. Pierard-Franchimont C, Lesuisse M, Humbert P, Delvenne P, Pierard GE. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf. 2012;7(5):357-60. [Crossref]  [PubMed]
14. Chen TJ, Chung WH, Chen CB, Hui RC, Huang YH, Lu YT, et al. Methotrexateinduced epidermal necrosis: a case series of 24 patients. J Am Acad Dermatol. 2017;77(2):247-55.e242. [Crossref]  [PubMed]
15. Valeyrie-Allanore L, Bastuji-Garin S, Guegan S, Ortonne N, Bagot M, Roujeau JC, et al. Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol. 2013;68(2):e29-e35. 16. Samhaber KT, Bertsch HP, Schon MP, Haenssle HA. In vivo reflectance confocal microscopy of erythema multi formeand Stevens-Johnson syndrome: a histopathological correlation based on a case series. J Ger Soc Dermatol. 2017;15(5):573-6. [Crossref]  [PubMed]
16. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-85. [Crossref]  [PubMed]
17. Knowles S, Shear NH. Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Ther. 2009;22(5):441-51. [Crossref]  [PubMed]
18. Mahar PD,Wasiak J, Cleland H, Watters D, Paul E, Marsh P, et al. Mortality and use of the auxiliary score in extensive toxic epidermal necrolysis patients admitted to an adult burns referral centre. Dermatology. 2013;227(2): 180-5. [Crossref]  [PubMed]
19. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54(1):108-15. [Crossref]  [PubMed]
20. Quirke KP, Beck A, Gamelli RL, Mosier MJ A 15- year review of pediatric toxic epidermal necrolysis. J Burn Care Res. 2015;36(1):130-6. [Crossref]  [PubMed]
21. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115(2):149- 53. [Crossref]  [PubMed]
22. Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. The Epidemiology of StevensJohnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240-7. [Crossref]  [PubMed]
23. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149- 53. [Crossref]  [PubMed]
24. Bansal S, Garg VK, Sardana K, Sarkar R. A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of toxic epidermal necrolysis. Int J Dermatol. 2015;54(1):e18-e26. [Crossref]  [PubMed]
25. Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, et al. Evaluation of SCORTEN on a cohort of patients with StevensJohnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32(2):237-45. [Crossref]  [PubMed]
26. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555-62. [Crossref]  [PubMed]
27. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-20. [Crossref]  [PubMed]
28. Karami Z, Mesdaghi M, Karimzadeh P, Mansouri M, Taghdiri MM, Kayhanidoost Z, et al. Evaluation of lymphocyte transformation test results in patients with delayed hypersensitivity reactions following the use of anticonvulsant drugs. Int Arch Allergy Immunol. 2016;170(3):158-62. [Crossref]  [PubMed]
29. Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome-alternatives for lymphocyte transformation test. Clin Exp Allergy. 2013;43(9):1027-37. [Crossref]  [PubMed]
30. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333(24):1600-7. [Crossref]  [PubMed]
31. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson Syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129(11):1221-5. [Crossref]  [PubMed]
32. Maggio N, Firer M, Zaid H, Bederovsky Y, Aboukaoud M, Gandelman-Marton R,et al. Causative drugs of Stevens-Johnson syndrome and toxic epidermal necrolysis in Israel. J Clin Pharmacol. 2017;57(7):823-9. [Crossref]  [PubMed]
33. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. StevensJohnson syndrome and toxic epidermalnecrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1): 35-44. [Crossref]  [PubMed]
34. Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-4. [Crossref]  [PubMed]
35. Nayar N, Briscoe K, Fernandez Penas P. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother. 2016;39(3):149- 52. [Crossref]  [PubMed]
36. Ou GJ, Wang J, Ji X, Yu H, Jiang L, Li L, et al. A study of HLA-B*15:02 in 9 different Chinese ethnics:implications for carbamazepine related SJS/TEN. HLA. 2017;89(4):225-9. [Crossref]  [PubMed]
37. Ramirez E, Bellon T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017;115:168-78. [Crossref]  [PubMed]
38. Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88(1):78-86. [Crossref]  [PubMed]
39. Niihara H, Kaneko S, Ito T, Sugamori T, Takahashi N, Kohno K, et al. HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. J Dermatol Sci 2013;71(2): 150-2. [Crossref]  [PubMed]
40. Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, et al. Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol. 2017;44(6):835-43. [Crossref]  [PubMed]
41. Yang F, Xuan J, Chen J, Zhong H, Luo H, Zhou P, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J. 2016; 16(1): 83-7. [Crossref]  [PubMed]
42. Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions Pharmacogenet Genomics. 2015;25(8):402- 11. [Crossref]  [PubMed]
43. Ueta M, Sawai H, Shingaki R, Kawai Y, Sotozono C, Kojima K,et al. Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. J Hum Genet. 2017;62(4):485-9. [Crossref]  [PubMed]
44. Ciccacci C, Latini A, Politi C,Mancinelli S, MarazziMC, Novelli G, et al. Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. Eur J Clin Pharmacol. 2017. [Crossref]  [PubMed]
45. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525-34. [Crossref]  [PubMed]
46. Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013; 69(11):1909-16. [Crossref]  [PubMed]
47. Pichler WJ. Pharmacological interaction of drugs with antigenspecific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301-5. [Crossref]  [PubMed]
48. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683- 93. [Crossref]  [PubMed]
49. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119(1):225-30. [Crossref]  [PubMed]  [PMC]
50. Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, et al. TNF-alpha and IFN-gamma are potential inducers of Fas mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133(2):489- 98. [Crossref]  [PubMed]
51. Correia O, Delgado L, Barbosa IL, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol. 2002;47(1):58-62. [Crossref]  [PubMed]
52. Tapia B, Padial A, Sanchez-Sabate E, et al. Involvement of CCL27-CCR10 interactions in druginduced cutaneous reactions. J Allergy Clin Immunol. 2004;114(2):335-40. [Crossref]  [PubMed]
53. Tocco-Tussardi I, Huss F, Presman B. Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center. J Cutan Pathol. 2017;44(5):420-32. [Crossref]  [PubMed]
54. Monteiro D, Egipto P, Barbosa J, Horta R, Amarante J, Silva P, et al. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome). Cutan Ocul Toxicol. 2017;36(2):163- 8. [Crossref]  [PubMed]
55. Weinand C, Xu W, Perbix W, Lefering R, Maegele M, Rathert M,et al. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns. 2013; 39(7):1449-55. [Crossref]  [PubMed]
56. Pannu BS, Egan AM, Iyer VN. Phenytoin induced Steven-Johnson syndrome and bronchiolitis obliterans-case report and review of literature. Respir Med Case Rep. 2016;17:54-6. [Crossref]  [PubMed]  [PMC]
57. Heye P, Descloux A, Singer G, Rosenberg R, Kocher T. Perforated sigmoid diverticulitis in the presence of toxic epidermal necrolysis. Case Rep Dermatol. 2016;6(1):49-53. [Crossref]  [PubMed]  [PMC]
58. Petukhova TA, Maverakis E, Ho B, Sharon VR Urogynecologic complications in Stevens-Johnson syndrome and toxic epidermal necrolysis: Presentation of a case and recommendations for management. JAAD Case Rep. 2016;2(3):202-5. [Crossref]  [PubMed]  [PMC]
59. Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, et al. Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology. 2016;63(3):993-9. [Crossref]  [PubMed]
60. Harimoto N, Wang H, Ikegami T, Takeishi K, Itoh S, Yamashita YI,et al. Education and Imaging. Hepatology: rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. J Gastroenterol Hepatol. 2015;30(4):656. [Crossref]  [PubMed]
61. Chow LL, Shih KC, Chan JC, Lai JS, Ng AL. Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. BMC Ophthalmol. 2017;17(1):65. [Crossref]  [PubMed]  [PMC]
62. Catt CJ, Hamilton GM, Fish J, Mireskandari K, Ali A. Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Am J Ophthalmol. 2016;166:68-75. [Crossref]  [PubMed]
63. Yang CW, Cho YT, Chen KL, Chen YC, Song HL, Chu CY. Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2016;96(4):525-9. [Crossref]  [PubMed]
64. Kreft B, Lieser U, Haase R, Marsch WC, Wohlrab J. Extensive hypertrophic scarring after toxic epidermal necrolysis in a child. Pediatr Dermatol. 2014;31(4):527-8. [Crossref]  [PubMed]
65. Chantaphakul H, Sanon T, Klaewsongkram J Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Ther Med. 2015;10(2): 519-24. [Crossref]  [PubMed]  [PMC]
66. Lim VM, Do A, Berger TG, Nguyen AH, DeWeese J, Malone JD, et al. A decade of burn unit experience with Stevens-Johnson syndrome/ toxic epidermal necrolysis: clinical pathological diagnosis and risk factor awareness. Burns. 2016;42(4):836-43. [Crossref]  [PubMed]
67. McCullough M, Burg M, Lin E, Peng D, GarnerW. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience. Burns. 2017;43(1):200-5. [Crossref]  [PubMed]
68. Xia W, Mao C, Luo X, Xu J, Chen X, Lin C. A 13- year retrospective study evaluating the efficacy of using air-fluidised beds for toxic epidermal necrolysis patients. Australas J Dermatol. 2016;57(3):205-9. [Crossref]  [PubMed]
69. Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, WhyteCroasdaile S, et al. Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2016;175(2):422-4. [Crossref]  [PubMed]
70. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/ toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8. [Crossref]  [PubMed]
71. Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a casecontrol analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol. 2012;167(3):555-62. [Crossref]  [PubMed]
72. Araki Y, Sotozono C, Inatomi T, Ueta M, Yokoi N, Ueda E, et al. Successful treatment of StevensJohnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147(6): 1004-11, 1011.e1001. [Crossref]  [PubMed]
73. Kim HI, Kim SW, Park GY, Kwon EG, Kim HH, Jeong JY, et al. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med. 2012;27(2):203-10. [Crossref]  [PubMed]  [PMC]
74. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139(1):26-32. [Crossref]  [PubMed]
75. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol. 2003;139(1):39-43. [Crossref]  [PubMed]
76. Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review andmeta-analysis. JAMA Dermatol. 2017;153(6) :514-22. [Crossref]  [PubMed]  [PMC]
77. Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, et al. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol. 2013; 79(4):506-11. [Crossref]  [PubMed]
78. Mohanty S, Das A, Ghosh A, Sil A, Gharami RC, Bandyopadhyay D, et al. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson syndrome/toxic epidermal necrolysis: a record-based study. Indian J Dermatol Venereol Leprol. 2017;83(3):312- 6. [Crossref]  [PubMed]
79. Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for StevensJohnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76(1):106-13. [Crossref]  [PubMed]
80. Giudice G, Maggio G, Bufano L, Memeo G, Vestita M. Management of toxic epidermal necrolysis with plasmapheresis and cyclosporine a: our 10 years' experience. Plast Reconstr Surg Glob Open. 2017;5(2):e1221. [Crossref]  [PubMed]  [PMC]
81. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352 (9140): 1586-9. [Crossref]  [PubMed]
82. Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014; 71(2):278-83. [Crossref]  [PubMed]
83. Chong I, Chao A. Stevens-Johnson syndrome/ toxic epidermal necrolysis and treatment with a biologic: a case report. Perm J21. 2017. [Crossref]  [PubMed]  [PMC]